An updated analysis of the GADOLIN study confirms the PFS benefit of obinutuzumab and bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma.
Journal of Clinical Oncology
Original Article: Updated GADOLIN Study Shows Survival Benefit in Indolent NHL